Strata Oncology Completes $90 Million Series C Financing

Strata Oncology completed a $90 million Series C financing, bringing the company’s total financing to over $130 million since its inception. The proceeds will be used to accelerate the development of Strata Oncology’s personalized minimal residual disease (MRD) assay for early-stage cancers and advance its pipeline of novel RNA-based treatment selection tests for solid tumors.

Wellington Management led the financing and was joined by new investors including Cormorant Asset Management, Monashee Investment Management and Highside Capital Management. Strata Oncology’s existing investors, including Pfizer Ventures, Merck Global Health Innovation Fund, Arboretum Ventures, Deerfield Management, Baird Capital and Renaissance Venture Capital Fund also participated in the financing. J.P. Morgan served as sole placement agent. Read more.

Total
0
Shares
Related Posts